ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 P&L / Income Statement

ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Customer. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

307,959,000 US dollars

Cost of product sales

28,316,000 US dollars

Gross profit (calculated)

279,643,000 US dollars

Operating expenses (calculated)

241,807,000 US dollars

Income from operations

37,836,000 US dollars

Other income (expense), net (calculated)

8,637,000 US dollars

Income before income taxes

46,473,000 US dollars

Income tax expense

14,973,000 US dollars

Net loss

31,500,000 US dollars

NUPLAZID

183,132,000 US dollars

DAYBUE products

124,827,000 US dollars

Research and development

81,555,000 US dollars

Selling, general and administrative

160,252,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.